Gelteq Limited Inc - GELS Net Assets per Single Share

Graphic logo of gelteq.com (GELS)

The investment potential of Gelteq Limited (GELS) is based on future licensing deals with pharma behemoths, as revenue is currently limited by testing. The current book value per share clearly demonstrates the net asset trend, where 0.84 shows the current volume of this metric. The company's foundation is built on FDA-protected patents for oral gels and a high-demand line of convenient tablet alternatives for people with dysphagia.

Gelteq Limited - GELS Net Assets per Share (period 10/30/2024 - 10/27/2026)

Summary analytical data breakdowns for Gelteq Ltd (GELS)

- price and consensus price forecast:
Price Chart Gelteq Limited Inc|GELS - Price Target Chart
- market capitalization data:
Market Value Gelteq Limited|GELS - Company Buyout Price
- book capitalization data:
Net Assets per Single Share Gelteq|GELS - Book Valuation of Business|Market Value to Book Value Ratio gelteq.com|GELS - Total Asset Value of Company
- debt and liquidity data:
Total Debt to Capital Gelteq Limited|GELS - Long-Term Liabilities to Capital|Short-Term Debt to Capital Gelteq Limited Inc|GELS - Company Total Debt|Debts to Book Capitalization Gelteq Limited
Analysis of all company metrics:gelteq.com GELS
Finished products of Gelteq Ltd

Book value per share determines the portion of net assets attributable to a single security, serving as a measure of the company's intrinsic value upon the liquidation of all liabilities. By analyzing the book value per share, an investor can see the tangible foundation of Gelteq Limited, which is bolstered by significant pricing power derived from unique patents for bioavailable gels, confirming the resilience and quality of the business.

Competitors of Gelteq Limited (GELS)

VRTX - Net Assets per Single Share|ALNY: Net Assets per Single Share|Insmed Incorporated - Net Assets per Single Share|UTHR (unither.com) - Net Assets per Share|BMRN: Net Assets per Single Share|Net Assets per Share BBIO|BGM - Net Assets per Single Share|Share Book Value Cogent Corp (COGT)|XERS: Book Value per Share|Net Asset Value per Share kerostx.com KROS|ARCT: Book Value per Share|ETON - Accounting Value per Share|Kamada Corp - Book Value per Share|Fulcrum Corp (FULC) - Net Assets per Share|ABEO (Abeona Therapeutics, Inc.) - Book Value per Share|Book Value per Share MREO|Net Assets per Single Share Protalix BioTherapeutics, Inc. (PLX)|Net Assets per Single Share pliantrx.com (PLRX)|Book Value per Share APLT|RNTX - Net Assets per Share|Accounting Value per Share Aytu Therapeutics|CMMB - Share Book Value|Book Value per Share SRXH|Polyrizon (PLRZ) - Net Asset Value per Share|Book Value per Share Aeterna Zentaris Inc (AEZS)|Equity per Share Cyclo Therapeutics, Inc (CYTH)|Inozyme Pharma, Inc. (INZY) - Accounting Value per Share|Accounting Value of a Share RPHM (reneopharma.com)|COSCIENS Biopharma (CSCI) - Net Assets per Single Share